Moderna vaccine shows 94.1% efficacy in trial: Study

Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna's Covid-19 vaccine have revealed 94.1 per cent efficacy of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study.

By December 31, 2020 at 01:35PM

Read More https://timesofindia.indiatimes.com/home/science/moderna-covid-19-vaccine-shows-94-1-per-cent-efficacy-in-trial-study/articleshow/80042725.cms